CD46 is another target present on myeloma-initiating cells,76 and a CD46-ADC has shown modest anti-myeloma activity in a phase I trial,77 but, again, moderate monocyte and granulocyte expression may necessitate additional engineering strategies to prevent longer-term cytopenias than are seen with other TCRTs.77 Here, CD46 is linked to plasma cell myeloma.